Genetic predictors of survival in behavioral variant frontotemporal degeneration.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31537715.
- Also identified by DOI 10.1212/WNL.0000000000008387 and PMC identifier 6946477.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine autosomal dominant genetic predictors of survival in individuals with behavioral variant frontotemporal degeneration (bvFTD). A retrospective chart review of 174 cases with a clinical phenotype of bvFTD but no associated elementary neurologic features was performed, with diagnosis either autopsy-confirmed (n = 57) or supported by CSF evidence of non-Alzheimer pathology (n = 117). Genetic analysis of the 3 most common genes with pathogenic autosomal dominant mutations associated with frontotemporal degeneration was performed in all patients, which identified cases with <i>C9orf72</i> expansion (n = 28), progranulin (<i>GRN</i>) mutation (n = 12), and microtubule-associated protein tau <i>(MAPT)</i> mutation (n = 10). Cox proportional hazards regressions were used to test for associations between survival and mutation status, sex, age at symptom onset, and education. Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a <i>GRN</i> mutation (HR 2.423, 95% CI 1.237, 4.744), <i>MAPT</i> mutation (HR 8.056, 95% CI 2.938, 22.092), and <i>C9orf72</i> expansion (HR 1.832, 95% CI 1.034, 3.244) were each individually associated with shorter survival relative to sporadic bvFTD. A mutation on the <i>MAPT</i> gene results in an earlier age at onset than a <i>C9orf72</i> expansion or mutation on the <i>GRN</i> gene (<i>p</i> = 0.016). Our findings suggest that autosomal dominantly inherited mutations, modulated by age at symptom onset, associate with shorter survival among patients with bvFTD. We suggest that clinical trials and clinical management should consider mutation status and age at onset when evaluating disease progression.
Medical subject headings
- Frontotemporal Dementia
- Survival Rate